Secukinumab for plaque psoriasis

被引:2
|
作者
Ordenes-Cavieres, Gonzalo [1 ,2 ]
Andino-Navarrete, Romina [2 ,3 ]
机构
[1] Pontificia Univ Catolica Chile, Fac Med, Santiago, Chile
[2] Proyecto Epistemon, Santiago, Chile
[3] Pontificia Univ Catolica Chile, Fac Med, Dept Dermatol, Santiago, Chile
来源
MEDWAVE | 2018年 / 18卷 / 07期
关键词
Plaque psoriasis; biological treatments; secukinumab; Epistemonikos; GRADE;
D O I
10.5867/medwave.2018.07.7363
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Biological treatments have appeared as the main alternative for the management of patients with plaque psoriasis that do not respond to conventional treatment. So, evaluating its actual efficacy and safety is needed. Methods We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. Results and conclusions We identified 21 systematic reviews including ten studies overall, of which all were randomized trials. We concluded secukinumab achieves clinical improvement in patients with plaque psoriasis, although it is probably associated with serious adverse effects.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
    Langley, Richard G.
    Elewski, Boni E.
    Lebwohl, Mark
    Reich, Kristian
    Griffiths, Christopher E. M.
    Papp, Kim
    Puig, Lluis
    Nakagawa, Hidemi
    Spelman, Lynda
    Sigurgeirsson, Bardur
    Rivas, Enrique
    Tsai, Tsen-Fang
    Wasel, Norman
    Tyring, Stephen
    Salko, Thomas
    Hampele, Isabelle
    Notter, Marianne
    Karpov, Alexander
    Helou, Silvia
    Papavassilis, Charis
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04): : 326 - 338
  • [22] Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
    Ribero, Simone
    Licciardello, Matteo
    Quaglino, Pietro
    Dapavo, Paolo
    CASE REPORTS IN DERMATOLOGY, 2019, 11 : 23 - 28
  • [23] Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis
    Rothstein, Brooke E.
    McQuade, Brianna
    Greb, Jacqueline E.
    Goldminz, Ari M.
    Gottlieb, Alice B.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 648 - 649
  • [24] Secukinumab-induced scar sarcoidosis in a patient with plaque psoriasis
    Hlaca, Nika
    Zagar, Tina
    Kastelan, Marija
    Brajac, Ines
    Prpic-Massari, Larisa
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (02) : E187 - E189
  • [25] Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
    Zundell, Melissa P.
    Gottlieb, Alice B.
    Stanger, Roselyn
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (02) : 97 - 99
  • [26] Drug survival of secukinumab for moderate-to-severe plaque psoriasis
    Lee, E. B.
    Reynolds, K. A.
    Pithadia, D. J.
    Wu, J. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : 222 - 222
  • [27] Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
    Johar, Asmah
    Thevarajah, Suganthi
    Heng, Agnes
    Chan, Lee Chin
    Ch'ng, Chin Chwen
    Safdar, Najeeb Ahmad Mohd
    Muniandy, Pubalan
    Taib, Tarita
    Tan, Wooi Chiang
    Tey, Kwee Eng
    DERMATOLOGY RESEARCH AND PRACTICE, 2019, 2019
  • [28] Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis
    Lu, Jia-Wei
    Zhang, Mei-Hua
    Gopee, Shehzad
    Lu, Yan
    JOURNAL OF DERMATOLOGY, 2021, 48 (10): : E494 - E495
  • [29] Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
    Hannah A. Blair
    Pediatric Drugs, 2022, 24 : 91 - 91
  • [30] Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
    Choi, Esther
    Thomson, Olivia
    Smith, David
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)